Equities

LIDDS

SE0001958612

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 07:23:46 10/05/2024 pm IST			5-day change	1st Jan Change
0.1705 ^SEK	0.00%		+2.71%	+57.87%

21/03	Sweden's Lidds Finalizes Purchase of Noviga Research	MT
21/03	LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	CI

LIDDS AB Approves Board Elections

January 09, 2024 at 05:40 pm IST

LIDDS AB (publ) at its EGN held on January 9, 2024 approved election of Daniel Lifveredson, Torbjörn Browall and Lars-Inge Sjöqvist as ordinary board members, and Bengt Viterius as deputy board member. Daniel Lifveredson was elected as Chairman of the Board.

Latest news about LIDDS AB

Sweden's Lidds Finalizes Purchase of Noviga Research	21/03	MT
LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	21/03	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
LIDDS AB (OM:LIDDS) signed an agreement to acquire Noviga Research AB.	29/01	CI
LIDDS AB Approves Board Elections	09/01	CI
Lidds AB Announces Resignation of Daniel Lifveredson from Board of Directors	07/12	CI
Lidds CFO to Take Over CEO Role; Shares Plunge	28/11	MT
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11	CI
LIDDS AB Announces CEO Changes	28/11	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/23/30	CI
LIDDS AB Announces CEO Changes	31/23/31	CI
LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc	07/23/07	CI
Max Mitteregger Resigns from the LIDDS's Board	03/23/03	CI
Anders MÃ¥nsson Plans to Leave the LIDDS AB as CEO	27/23/27	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2023	29/23/29	CI
LIDDS AB Announces Management Changes	13/23/13	CI
LIDDS AB Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/23/13	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/22/28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/22/25	CI
LIDDS AB Announces CEO Changes	15/22/15	CI
LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel	08/22/08	CI
LIDDS AB Appoint Executives	07/22/07	CI
Sweden's Lidds Obtains Patent for Drug Release Technology in Japan, South Korea	07/22/07	MT
LIDDS AB Announces Board Changes	01/22/01	CI

Chart LIDDS AB

Duration

Period

More charts

Company Profile

Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Companyâs portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.

Sector

Biotechnology & Medical Research

Calendar

15/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIDDS AB	+57.87%	2.15M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs